COMP <GO>
NVST vs JNJ // DIVIDEND YIELD & FCF PAYOUT SAFETY
Envista Holdings Corporation (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: NVST 5
— JNJ 9
■ METRIC PARITY
LAST: $23.51 (-4.47%) • MKT CAP: $3.95B
dividend-safety
0.00%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NVST VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NVST | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.70% | 67.90% | -13.20 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 5.10% | 25.50% | -20.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.5x | 18.5x | -2.00 | NVST | /valuation <GO> |
| Free Cash Flow Yield | 5.83% | 2.97% | +2.86 | NVST | /fcf-yield <GO> |
| Operating Margin | 7.90% | 34.70% | -26.80 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 1.70% | 28.50% | -26.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 8.30% | 6.00% | +2.30 | NVST | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.61 | 5.59 | -3.98 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | NVST | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.20% | -0.50 | NVST | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.7 | 60.4 | -12.69 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.93 | 1.08 | -0.15 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 78.2x | 23.0x | +55.20 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.95B | $662.49B | -$658.54B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NVST REV | JNJ REV | NVST GROSS % | JNJ GROSS % | NVST FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.72B | $94.19B | 54.7% | 67.9% | $230.4M | $19.70B |
| FY 2024 | $2.51B | $88.82B | 54.7% | 69.1% | $302.7M | $19.84B |
| FY 2023 | $2.57B | $85.16B | 44.0% | 44.0% | $160.2M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NVST // BETA 0.93
JNJ // BETA 1.08